铂耐药复发性卵巢癌化疗联合或化疗后使用贝伐珠单抗:AURELIA 试验的探索性分析
AURELIA 是一项开放标签随机 III 期试验,361 例铂耐药卵巢癌患者随机接受单纯化疗或化疗联合贝伐珠单抗。本探索性分析显示,单纯化疗组中 40%(72/182)的患者在疾病进展后接受了贝伐珠单抗;与从未使用贝伐珠单抗者相比,随机时即联合化疗使用贝伐珠单抗者死亡风险降低(HR=0.68,95%CI 0.52-0.90),进展后使用贝伐珠单抗者死亡风险亦降低(HR=0.60,95%CI 0.43-0.86)。作者认为,疾病进展后使用贝伐珠单抗可能干扰了 AURELIA 的总生存结果。
要点
- 单纯化疗组 182 例中 72 例(40%)在疾病进展后接受贝伐珠单抗,110 例(60%)从未使用。
- 与从未使用贝伐珠单抗相比,随机时即联合化疗使用贝伐珠单抗者死亡风险降低(HR=0.68,95%CI 0.52-0.90)。
- 与从未使用贝伐珠单抗相比,疾病进展后使用贝伐珠单抗者死亡风险降低(HR=0.60,95%CI 0.43-0.86)。
核心结论
- 作者认为,疾病进展后使用贝伐珠单抗可能干扰了 AURELIA 的总生存结果。
- 在这项非随机亚组的探索性分析中,无论是与化疗同时使用还是在单纯化疗疾病进展后使用贝伐珠单抗,均较未使用贝伐珠单抗改善了总生存。
- 作者认为,在铂耐药首次出现时即联合化疗使用贝伐珠单抗,可最大程度提高患者接受这一对铂耐药卵巢癌有效治疗的可能性。
研究设计与样本
- AURELIA 为开放标签随机 III 期试验(ClinicalTrials.gov:NCT00976911),361 例铂耐药卵巢癌女性随机接受单纯化疗或化疗联合贝伐珠单抗。
- 随机分配至单纯化疗的患者在疾病进展后可接受贝伐珠单抗。
- 本分析为事后分析,按三个亚组评估疗效与安全性:单纯化疗、化疗后疾病进展使用贝伐珠单抗、随机时即化疗联合贝伐珠单抗。
主要发现
- 随机分配至单纯化疗的 182 例患者中,72 例(40%)在疾病进展后接受贝伐珠单抗,110 例(60%)从未接受贝伐珠单抗。
- 这些亚组在基线及疾病进展时的患者与疾病特征无显著差异。
- 与从未接受贝伐珠单抗者相比,随机时即联合化疗使用贝伐珠单抗者死亡风险显著降低(HR=0.68,95%CI 0.52-0.90)。
- 与从未接受贝伐珠单抗者相比,疾病进展后使用贝伐珠单抗者死亡风险显著降低(HR=0.60,95%CI 0.43-0.86)。
- 贝伐珠单抗在随机时即使用与疾病进展后使用的耐受性相似。
临床怎么用
- 作者认为,在铂耐药首次出现时即联合化疗使用贝伐珠单抗,可最大程度提高患者接受这一对铂耐药卵巢癌有效治疗的可能性。
局限性
- 本分析为事后分析。
- 本分析为非随机亚组的探索性分析。
- 疾病进展后使用贝伐珠单抗可能干扰了 AURELIA 的总生存结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored the effect of bevacizumab use after disease progression (PD) in patients randomized to chemotherapy alone. PATIENTS AND METHODS: In AURELIA, 361 women with PROC were randomized to chemotherapy alone or with bevacizumab. Patients initially randomized to chemotherapy were offered bevacizumab after PD. Post hoc analyses assessed efficacy and safety in three subgroups: chemotherapy alone, chemotherapy followed by bevacizumab after PD, and chemotherapy plus bevacizumab at randomization. RESULTS: Of the 182 patients randomized to chemotherapy alone, 72 (40%) received bevacizumab after PD and 110 (60%) never received bevacizumab. There were no significant differences in patient and disease characteristics between these subgroups at baseline or the time of PD. Compared with patients never receiving bevacizumab, the risk of death was significantly reduced in patients receiving bevacizumab either upfront with chemotherapy [hazard ratio (HR) = 0.68, 95% confidence interval (CI) 0.52-0.90] or after PD (HR = 0.60, 95% CI 0.43-0.86). The tolerability of bevacizumab was similar with administration upfront or after PD. CONCLUSIONS: Post-PD bevacizumab use may have confounded OS results in AURELIA. In these exploratory analyses of non-randomized subgroups, bevacizumab use, either with chemotherapy or after PD on chemotherapy alone, improved OS compared with no bevacizumab. Combining bevacizumab with chemotherapy at first appearance of platinum resistance maximises the likelihood of patients receiving this active treatment for PROC. ClinicalTrials.gov: NCT00976911.
引用
- Bamias A, Gibbs E, Khoon Lee C, et al. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Ann Oncol. 2017. PMID: 28481967. doi:10.1093/annonc/mdx228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。